Daphne Taylor - 03 Mar 2023 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
SVP, CFO
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Issuer symbol
APVO
Transactions as of
03 Mar 2023
Net transactions value
$0
Form type
4
Filing time
07 Mar 2023, 15:41:12 UTC
Next filing
10 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +1,583 +41% 5,423 04 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Stock Option (right to buy) Award $0 +11,000 $0.000000 11,000 03 Mar 2023 Common Stock 11,000 $2.15 Direct F2
transaction APVO Restricted Stock Unit Award $0 +11,000 $0.000000 11,000 03 Mar 2023 Common Stock 11,000 Direct F1, F3
transaction APVO Restricted Stock Unit Options Exercise $0 -1,583 -33% $0.000000 3,167 04 Mar 2023 Common Stock 1,583 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 The option vests in three approximately equal annual installments beginning on March 2, 2024.
F3 The RSUs vest in three approximately equal annual installments beginning on March 2, 2024.
F4 On June 7, 2022, the reporting person was granted 4,750 RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023.